Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis

ConclusionThis meta-analysis demonstrated that the PFS and OS were significantly greater in patients with CRPC in those with higher testosterone levels than that of those with lower testosterone levels. In the subgroup analyses, lower testosterone levels were a consistently poor prognostic factor for OS in patients treated with ARTAs, but not in those treated with chemotherapy. Therefore, higher testosterone levels could be a useful biomarker to identify patient subgroups in which ARTAs should be preferentially recommended in the CRPC setting.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research